GBT Announces Participation at Upcoming Investor Conferences in March
March 05, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in March...
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
February 27, 2018 16:07 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter...
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
February 07, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Leerink Partners 7th Annual Global...
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
January 09, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted...
GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare...
GBT Appoints Wendy L. Yarno to Board of Directors
December 22, 2017 09:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of...
Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering
December 15, 2017 09:03 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and...
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
December 14, 2017 16:01 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and...
GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
December 11, 2017 07:00 ET
|
Global Blood Therapeutics, Inc.
-- Highlights Include Compassionate Access Case Studies, Pediatric Pharmacokinetic Data and Burden of Care Data -- -- Company Plans to Announce Top-Line Data from Part A of Phase 3 HOPE Study in...
GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
December 09, 2017 10:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of...